AMLXAMLXHealthcare · Drug Manufacturers - Specialty & Generic

AMLX Stock Forecast: Amylyx Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$38
−1.32% on the day

The 12 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. hold a median 12-month price target of $42 — +10.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$4.3B
Ticker Nerd rank
56 / 100
Median analyst target
$42
Analysts covering
12
Revenue$0.0
Operating income−$45.7M
Net income−$43.4M
Free cash flow−$31.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+78.0%
1M
+107.2%
YTD
+215.8%
1Y
+310.2%
From 52W high
−3.8%
From 52W low
+348.8%
$9
$40
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AMLX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Amylyx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
56 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Growth
87
Value
76
Volatility
54
Accruals
48
Issuance
40
Quality
35
Revisions
34
Size
27

Momentum (98): The shares have been drifting up relative to others.

Revisions (34): Analysts have, on balance, been cutting their forecasts.

Size (27): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AMLX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMLX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26AMLXHigh $55Median $42Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
11 Buy1 Hold0 Sell
Low $20Median $42High $55

The green dot is the last close — the median target sits +10.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
19 Aug 2026BairdMaintainsOutperform$28$52
19 Aug 2026GuggenheimMaintainsBuy$40$55
19 Aug 2026MizuhoMaintainsOutperform$30$42
18 Aug 2026HC Wainwright & Co.MaintainsBuy$34$55
17 Aug 2026MizuhoMaintainsOutperform$24$30
3 Aug 2026CitigroupMaintainsBuy
3 Aug 2026CitigroupMaintainsBuy$20$26
20 July 2026MizuhoMaintainsOutperform
20 July 2026MizuhoMaintainsOutperform$21$24
25 June 2026GuggenheimMaintainsBuy
25 June 2026GuggenheimMaintainsBuy$30$40
28 Apr 2026MizuhoMaintainsOutperform
25 Mar 2026HC Wainwright & Co.ReiteratesBuy
19 Mar 2026GuggenheimMaintainsBuy
4 Mar 2026HC Wainwright & Co.MaintainsBuy
3 Mar 2026StifelInitiatesBuy
20 Feb 2026B of A SecuritiesMaintainsBuy
10 Feb 2026HC Wainwright & Co.MaintainsBuy
7 Nov 2025HC Wainwright & Co.MaintainsBuy
17 Oct 2025CitigroupMaintainsBuy

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMLX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AMLX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Amylyx Pharmaceuticals, Inc. returned +310.2% against +19.6% for the S&P 500, dividends included.

AMLX vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Oct 25Jan 26Apr 26Jul 26AMLXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AMLX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

Amylyx Pharmaceuticals, Inc. (AMLX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.5×

Cheaper than 69% of US stocks

Price / sales
Price / book
17.8×

Cheaper than 6% of US stocks

EV / EBITDA
−25.1×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
Earnings growth (YoY)
Gross margin
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−74.7%

Higher than 16% of US stocks

Return on assets
−44.1%

Higher than 9% of US stocks

Dividend yield

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Amylyx Pharmaceuticals, Inc. (AMLX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Amylyx Pharmaceuticals, Inc. has a market value of $4.3B and an enterprise value of $4.1B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$152.1M.

  • Diluted earnings per share, trailing twelve months: $−1.43.

  • Free cash flow in the twelve months to 30 June 2026: −$126.7M.

  • Shares outstanding: 111.4M.

  • Trailing P/E: 2.5×; forward P/E: −33.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Amylyx Pharmaceuticals, Inc. employs 136 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

AMLX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AMLXAmylyx Pharmaceuticals, Inc.$4.3B
56
INDVIndivior Pharmaceuticals, Inc.$4.4B
97
AMRXAmneal Pharmaceuticals, Inc.$5.6B
80
LQDALiquidia Corp.$5.9B
78
KNSAKiniksa Pharmaceuticals International Plc$6.1B
98
LNTHLantheus Holdings, Inc.$6.5B
86
SUPNSupernus Pharmaceuticals, Inc.$2.6B
84

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Amylyx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AMLX news & analysis

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

The Motley Fool · 21 Aug 2026positive

Amylyx Pharmaceuticals' stock rose nearly 79% this week after analysts raised their price targets on the company and it launched a new round of capital raising.

Why it matters — For an Amylyx watcher, the sharp stock surge and analyst price-target hikes signal renewed investor confidence, while the capital raise could fund future operations or pipeline development.

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

Business Wire · 20 Aug 2026neutral

Amylyx Pharmaceuticals announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at $35.50 per share. The company also granted underwriters a 30-day option to purchase up to an additional 2,113,500 shares at the same price, less underwriting discounts and commissions.

Why it matters — AMLX watchers would care because this capital raise increases the company's cash position through the sale of new shares, which dilutes existing shareholders.

AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win

Zacks Investment Research · 19 Aug 2026positive

Amylyx's stock rose after its drug avexitide reduced hypoglycemic events by 55% in the Phase III LUCIDITY study, positioning the company for an FDA filing in post-bariatric hypoglycemia by the end of 2026.

Why it matters — The Phase III win and planned FDA filing signal progress for avexitide, a key pipeline candidate for Amylyx shareholders.

Why Amylyx Pharmaceuticals Stock Skyrocketed Today

The Motley Fool · 18 Aug 2026positive

Amylyx Pharmaceuticals' stock rose sharply after the company reported that its experimental GLP-1 treatment for chronic low blood sugar showed a favorable safety profile in a clinical study.

Why it matters — The positive safety data from the clinical study represents a notable development for Amylyx's GLP-1 pipeline candidate.

Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

Business Wire · 18 Aug 2026negative

Amylyx Pharmaceuticals announced it has commenced an underwritten public offering of $350.0 million of shares of its common stock. The company also intends to grant underwriters a 30-day option to purchase up to an additional $52.5 million of shares at the public offering price, less underwriting discounts and commissions.

Why it matters — The proposed offering reflects a significant capital raise that will affect Amylyx's share count, existing shareholders' ownership, and the company's cash position.

FAQ

Frequently asked questions about AMLX stock

What is the AMLX stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. have a median 12-month price target of $42, with estimates ranging from $20 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMLX stock a buy right now?

Of the 12 analysts covering Amylyx Pharmaceuticals, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Amylyx Pharmaceuticals, Inc. 56 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMLX?

As at 22 Aug 2026, Amylyx Pharmaceuticals, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will AMLX stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +10.1% from the last close, and Ticker Nerd's factor model ranks Amylyx Pharmaceuticals, Inc. 56 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMLX stock forecast for 2030?

No analyst covering Amylyx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $55 over the next 12 months.

How has AMLX stock performed over the past year?

Amylyx Pharmaceuticals, Inc. returned +310.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Amylyx Pharmaceuticals, Inc. do?

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for neurodegenerative diseases and endocrine conditions.

What is the latest news on AMLX?

The most recent item we track (The Motley Fool, 21 Aug 2026): "Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week". Amylyx Pharmaceuticals' stock rose nearly 79% this week after analysts raised their price targets on the company and it launched a new round of capital raising.

Company

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for neurodegenerative diseases and endocrine conditions. The company’s current pipeline includes investigational programs such as avexitide, a GLP-1 receptor antagonist studied for post-bariatric hypoglycemia and congenital hyperinsulinism, as well as candidates being evaluated for rare neurological and metabolic disorders. Amylyx Pharmaceuticals, Inc. concentrates on diseases with high unmet medical need and applies biomarker-driven and mechanistic research to guide its drug development efforts. Based in Cambridge, Massachusetts, the company operates as a single business segment centered on research and development of novel therapeutics for serious conditions.

CEO Mr. Joshua B. Cohen · 136 employees · United States · https://amylyx.com